Vaxart (VXRT)

• Market cap: $72.6M
• 1 day: -7.50%
• 5 days: -14.03%
• 1 month: -38.36%
• 3 months: -58.39%
• 6 months: -59.40%
• Year to date: -55.74%
• 1 year: -58.28%
• 5 years: -89.93%
• 10 years: -98.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Employees: 105

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

15% more call options, than puts

Call options by funds: $133K | Put options by funds: $116K

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

0.81% less ownership

Funds ownership: 16.52% [Q3] → 15.71% (-0.81%) [Q4]

7% less funds holding

Funds holding: 99 [Q3] → 92 (-7) [Q4]

26% less capital invested

Capital invested by funds: $31.9M [Q3] → $23.7M (-$8.23M) [Q4]

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 529% upside
• Avg. target: $2 529% upside
• High target: $2 529% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target

529% upside $2

Buy Maintained

27 Mar 2025